Профиль BioInvent International ABShs
BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F.I.R.S.T., a tool for drug development and n-CoDeR, an antibody library. The company was founded in 1996 and is headquartered in Lund, Sweden.